Premium
Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro‐inflammatory cytokines
Author(s) -
Min ChangKi,
Lee Seok,
Kim YooJin,
Eom KiSeong,
Lee JongWook,
Min WooSung,
Kim ChunChoo,
Cho ChulSoo,
Park Gyeongsin
Publication year - 2006
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.0902-4441.2005.t01-1-ejh2437.x
Subject(s) - bortezomib , multiple myeloma , medicine , proteasome inhibitor , vasculitis , tumor necrosis factor alpha , refractory (planetary science) , dexamethasone , immunology , disease , biology , astrobiology
The proteasome inhibitor, bortezomib, has anti‐myeloma activity even in myeloma cells refractory to multiple prior treatments. Bortezomib blocks the production of nuclear factor‐ κ B (NF κ B)‐mediated pro‐inflammatory cytokines. We report a patient with myeloma who developed a cutaneous leucoclastic vasculitis (LV) after bortezomib treatment. The patient with LV exhibited a marked increase in serum levels of IL‐6, TNF‐ α , and C‐reactive protein (CRP). Bortezomib administration may enhance the release of pro‐inflammatory cytokines, which might play a role in bortezomib‐induced cutaneous LV.